Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Delayed Quote. Delayed  - 07/27 05:19:56 pm
249.1 CHF   -0.48%
01:22p GSK chases next biotech asthma drug with 175 million pounds J&J d..
06:46a ROCHE : Architectural, engineering and planning services
07/22 ROCHE : F. Hoffmann-La Roche Announces Half Year Results 2016
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on ROCHE HOLDING LTD.
01:22p GSK chases next biotech asthma drug with 175 million pounds J&J deal
06:46a ROCHE : Architectural, engineering and planning services
07/22 ROCHE : F. Hoffmann-La Roche Announces Half Year Results 2016
07/22 ROCHE : Diagnostics Operations Assigned Patent
07/22 ROCHE : Site finds its buyer
07/22 UNILEVER : and Roche results better than expected
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/21 ROCHE : Bloomfield firm buys roche campus; medical school lease signed
07/21 ROCHE : S campus sold; lease signed for medical school
07/21DJROCHE : Sales Rise on Cancer Drugs -- Update
07/21DJROCHE : Sales Rise on Cancer Drugs
07/21DJROCHE : Net Profit Up 4% in First Half
07/21DJROCHE : 1st Half Net Profit Up 4% to CHF5.5 Billion
07/19 ROCHE : Genentech Provides Update on Phase III Study of Gazyva in People with Pr..
07/18DJROCHE : 1st Half 2016 -- Forecast
07/18 ROCHE : provides update on phase III study of Gazyva/Gazyvaro in people with pre..
07/18 GENENTECH : Provides Update on Phase III Study of Gazyva® in People With Previou..
07/15 ROCHE : After all these years ... Berry Pond still beloved by locals
07/14 REMINDER : Invitation to Roche's Half Year Results 2016
07/14DJCravath, Swaine & Moore Names Faiza Saeed as Presiding Partner
07/13 BioMarin Pharmaceutical shares rise after possible takeover from Roche
07/12 FOUNDATION MEDICINE INC. : COO Sells $114,766.65 in Stock
07/12 ROCHE : FDA Approves Xolair for Allergic Asthma in Children 6-11
07/11 ROCHE : FDA approves Xolair to treat allergic asthma in children
07/11 ROCHE : Module Designed to Meet Demand for Increased Diagnostic Testing
07/10 ROCHE : Newly reopened Berry Pond is still loved by locals
07/09 BIOMARIN PHARMACEUTICAL JUMPS : Stock Rises 9.1%
07/08 ROCHE : Former Roche v-p in Quebec out on bail after getting 18-month prison ter..
07/08 ROCHE : 1st HPV Test for Use With Preservative Fluid
07/07 ROCHE : FDA Approves Genentech’s Xolair® (omalizumab) for Allergic Asthma ..
07/07 CHUGAI PHARMACEUTICAL : Findings from Chugai Pharmaceutical Has Provided New Inf..
07/07 ROCHE : FDA approves first HPV test for use with SurePath Preservative Fluid
07/06 ROCHE : Former Roche v-p in Quebec gets 18-month prison term for fraud
07/05 GLOBAL GENE AMPLIFICATION MACHINE CO : Roche, Life, ABI, AGS, Geneinn, Hema Medi..
07/05 ROCHE : Infringement procedure against Roche - EMA update
07/05 REMINDER : Roche Analyst Event on Diagnostics Division at AACC 2015
07/05 ROCHE : Mains gas
07/04 ROCHE : Infringement procedure against Roche – EMA update
07/04 ROCHE : acquisition of a floor area of artistic gymnastics
07/04 ROCHE : Sri Lankan Court Dismisses F. Hoffmann-La Roche's Lawsuit To Ban the Dis..
07/01 ROCHE : Diagnostics Operations Assigned Patent
07/01 ROCHE : Street Crews to fill cracks
06/30 FOUNDATION MEDICINE : NCI - Significant expansion of data available in the Genom..
06/30 ROCHE : Uch Takes Delivery of N100 Million Laboratory Equipment
06/29 FOUNDATION MEDICINE : Announces Release of Molecular Information from Foundation..
06/28 ROCHE : Ocrevus marketing applications under review by the EMA and FDA
06/28 ROCHE : Hetero launches colorectal cancer drug
06/28 ROCHE : FDA Grants Priority Review for Genentechs OCREVUS (ocrelizumab) Biologic..
06/28 ROCHE : marketing applications for review of OCREVUS® (ocrelizumab) in two forms..
06/28 ROCHE : marketing applications for review of Ocrevus (ocrelizumab) in two forms ..
06/28 ROCHE : FDA Grants Priority Review for Genentech’s OCREVUS™ (ocreliz..
06/25 ROCHE : Master of work on the Layouts and rehabilitation
06/24 ROCHE : Diagnostics Operations Assigned Patent
06/23 U.S. Supreme Court weighs review of canceled patent on prenatal test
06/23 ROCHE : Federal Contracts Awarded by Federal Agencies in South Dakota (June 23)
06/23 ROCHE : Nearly 10 million U.S. adults severely nearsighted
06/23 CONTRACT AWARD - 68-- NOXIOUS WEEDS : Crow creek agency
06/23 FOUNDATION MEDICINE, INC. : Submission of Matters to a Vote of Security Holders ..
06/23 ROCHE : Invitation to Roche's Half Year Results 2016
06/22 Roche CEO 'sleeps better' as risk to drugmaker's growth recedes
06/22 CHUGAI PHARMACEUTICAL : and Maruho Announce the Launch of'Marduox Ointment,' for..
06/21 ROCHE : Harbor residents concerned of drainage to Westcott Bay
06/20 FOUNDATION MEDICINE : Shorted Shares Increased 0.65% After Market Selling
06/20 ROCHE : launches the new cobas e 801 module, helping hospitals meet the demand f..
06/20 Novartis aims to triple biosimilar drugs by 2020
06/20 ALLERGAN : 1 Stock to Invest in Big Pharma
06/16 CANCER TREATMENT : Patent Issued for Predictive Biomarker for Cancer Treatment w..
06/16 FOUNDATION MEDICINE : Data From a Study Utilizing FoundationOne® Heme Indicates ..
06/16 Foundation Medicine Presents New Data at ASCO 2016 Demonstrating that Foundat..
06/16 Foundation Medicine and AstraZeneca Enter Strategic Collaboration for Lynparz..
06/16 ROCHE : EC approves Gazyvaro plus bendamustine in follicular lymphoma
06/16 ROCHE : employees raise funds for vulnerable children in over 90 communities aro..
06/16 ROCHE : Gazyvaro approved in Europe in combination with bendamustine for people ..
06/14 ROCHE : Tecentriq to dominate the bladder cancer market, says GlobalData
06/13 GOOD PHARMA : How Marketing creates Value in Pharma
1  2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ( CHF)
Sales 2016 51 205 M
EBIT 2016 17 846 M
Net income 2016 11 503 M
Debt 2016 10 961 M
Yield 2016 3,41%
P/E ratio 2016 18,53
P/E ratio 2017 16,74
EV / Sales 2016 4,46x
EV / Sales 2017 4,14x
Capitalization 217 229 M
More Financials
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 298  CHF
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Daniel O'Day COO-Roche Pharmaceuticals Division
Roland Diggelmann COO-Roche Diagnostics Division
Alan Hippe Chief Financial & Information Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-9.99%218 902
JOHNSON & JOHNSON21.84%344 243
PFIZER INC.14.10%223 368
NOVARTIS AG-5.30%219 971
MERCK & CO., INC.10.49%161 542
BRISTOL-MYERS SQUIBB C..9.11%125 298
More Results